On Monday, the U.S. Food and Drug Administration (FDA) approved Amphastar Pharmaceuticals, Inc.’s (NASDAQ:AMPH) Abbreviated New Drug Application (ANDA) for Iron Sucrose Injection, USP 50mg/2.5mL, ...

Results of the review also found that 18 adverse events occurred in a total of 13 patients (18.1% of patients; 6.6% of infusions). For pediatric patients with inflammatory bowel disease (IBD), ...

Expands access to much-needed iron therapy for millions of US patients Builds Sandoz portfolio of high-quality injectable iron therapies and sets stage for future launches Strengthens US supply of ...

Iron repletion is a very common and necessary therapy for patients with NDDCKD. Oral iron supplementation is frequently not tolerated and sometimes inadequate to replete the body's iron stores. The ...

Amphastar has received permission from the Food and Drug Administration for iron sucrose injection, 50mg/2.5ml, 100mg/5ml and 200mg/10ml in single-dose vials, previously referred to as AMP-002. Iron ...

Iron Sucrose (Feroject) is a mineral iron, prescribed for iron deficiency anemia especially for kidney failure patients. It replenishes body iron stores in patients with iron deficiency. The ...

Iron Sucrose is a mineral iron, prescribed for iron deficiency anemia especially for kidney failure patients. Aloglutamol can cause a decrease in the absorption of Iron saccharate resulting in a ...

Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL Strengths; Provides Eligibility for 180 Days of Exclusivity Viatris Chief R&D Officer Philippe Martin said, ...

Purpose: The safety of high-dose iron sucrose infusion in hospitalized patients with chronic kidney disease was studied. Methods: A retrospective analysis was conducted at a 478-bed community hospital ...